Director, Biochemistry and Biophysics
Auron Therapeutics, Massachusetts, United States
Betty joined Auron Therapeutics in January 2021. She is a data-driven and motivated scientific investigator with 15 years of experience building and leading biochemistry and lead discovery capabilities. Betty’s interest and expertise include advancing small molecules from various hit finding approaches (including DNA-encoded library screening) to IND filing, developing innovative assays to interrogate new modalities and their biochemical mechanisms of action, and working collaboratively to build infrastructure for supporting new R&D programs. Prior to joining Auron, she worked at Civetta Therapeutics, Kymera Therapeutics, X-Chem Pharmaceuticals, H3 Biomedicine, and Galenea Corporation. Betty has a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, a M.S. in Molecular and Cell Biology from Brandeis University, where she also received bachelor’s degrees in Biochemistry, Biology, and French Language and Literature.
Disclosure information not submitted.
Monday, February 7, 2022
4:00 PM – 4:30 PM